SARS-CoV-2 T Cell Immunity

In collaboration with Charité (Prof. Andreas Thiel) the T Cell immune response to SARS-CoV-2 infection and vaccination was systematically analyzed. For the first time, the presence of SARS-CoV-2-reactive T cells was revealed not only in patients with COVID-19 but also in healthy donors (Braun et al., Nature 2020). Upon vaccination with BNT162b2, strong T cell immunity was developed with kinetics resemblingthose of secondary immune responses. Furthermore, a universal immunodominant coronavirus-specific peptide epitope (iCope) was identified (Loyal et al., medRxiv 2021).



  • SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
    Braun et al., Nature 2020 - PMID: 32726801 
  • Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
    Loyal et al., medRxiv (2021) - PMID: 34465633 


Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité–Universitätsmedizin Berlin, Berlin, Germany (Prof. Andreas Thiel)

Check our list of products, click and go.

Get a quote